JP2012505162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505162A5 JP2012505162A5 JP2011530339A JP2011530339A JP2012505162A5 JP 2012505162 A5 JP2012505162 A5 JP 2012505162A5 JP 2011530339 A JP2011530339 A JP 2011530339A JP 2011530339 A JP2011530339 A JP 2011530339A JP 2012505162 A5 JP2012505162 A5 JP 2012505162A5
- Authority
- JP
- Japan
- Prior art keywords
- macular degeneration
- therapy
- subject
- alkyl
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002780 macular degeneration Diseases 0.000 claims description 23
- 238000002560 therapeutic procedure Methods 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 229940127557 pharmaceutical product Drugs 0.000 claims description 10
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 9
- 238000012014 optical coherence tomography Methods 0.000 claims description 8
- -1 scyllo-inositol compound Chemical class 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000003981 vehicle Substances 0.000 claims description 6
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims description 5
- 230000002137 anti-vascular effect Effects 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000000649 photocoagulation Effects 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 238000002428 photodynamic therapy Methods 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical group COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims description 2
- 201000004569 Blindness Diseases 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 229940076783 lucentis Drugs 0.000 claims description 2
- 229940092110 macugen Drugs 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 230000004393 visual impairment Effects 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 150000002431 hydrogen Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10409408P | 2008-10-09 | 2008-10-09 | |
| US61/104,094 | 2008-10-09 | ||
| PCT/CA2009/001448 WO2010040232A1 (en) | 2008-10-09 | 2009-10-09 | Use of scyllo-inositols for the treatment of macular degeneration-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012505162A JP2012505162A (ja) | 2012-03-01 |
| JP2012505162A5 true JP2012505162A5 (cg-RX-API-DMAC7.html) | 2012-11-22 |
Family
ID=42099427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011530339A Pending JP2012505162A (ja) | 2008-10-09 | 2009-10-09 | 黄斑変性症関連障害を処置するためのｓｃｙｌｌｏ−イノシトールの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100093648A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2349233A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012505162A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009301603A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2740124A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010040232A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201102640B (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| EP2044951A1 (en) | 2007-10-02 | 2009-04-08 | Merz Pharma GmbH & Co. KGaA | The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases |
| US20210121430A1 (en) | 2011-07-18 | 2021-04-29 | Prn Physician Recommended Nutriceuticals, Llc | Omega-3 fatty acid supplementation for use in treating dry eye |
| US9115078B2 (en) | 2011-07-18 | 2015-08-25 | Physicians Recommended Nutriceuticals, Llc | Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands |
| US10709680B2 (en) | 2011-07-18 | 2020-07-14 | Physicians Recommended Nutriceuticals, Llc | Methods for treating dry eye |
| US9381183B2 (en) | 2012-07-18 | 2016-07-05 | Physicians Recommended Nutriceuticals, Llc | Methods for improving the quality of the meibum composition of meibomian glands |
| AU2013269594C1 (en) | 2012-06-01 | 2020-12-17 | Novartis Ag | Syringe |
| TW201412325A (zh) | 2012-06-20 | 2014-04-01 | 梅茲製藥有限兩合公司 | 用於治療患有青光眼及其他退化性眼疾之人類視力喪失的間隔醫療 |
| CN103070992B (zh) * | 2013-01-11 | 2014-07-02 | 管学刚 | 一种治疗高度近视黄斑出血药物 |
| RU2716256C2 (ru) | 2014-01-28 | 2020-03-11 | Бак Инститьют Фо Ресеч Он Эйджинг | Способы и композиции для уничтожения стареющих клеток и для лечения заболеваний и расстройств, ассоциированных со старением |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
| US9173915B1 (en) | 2014-10-10 | 2015-11-03 | Peter F. Kador | Antioxidant eye drops |
| EP3233174B1 (en) * | 2014-12-19 | 2021-03-31 | Kemin Industries, Inc. | Intraocular delivery of bioactive molecules using iontophoresis |
| PT3416622T (pt) * | 2016-02-15 | 2023-08-28 | Kemin Ind Inc | Lipossomas com carga positiva como transportadores de moléculas lipofílicas |
| EP3787634A4 (en) * | 2018-05-03 | 2022-02-23 | NormOxys, Inc. | INOSITOL-BASED IMMUNOTHERAPIES |
| US20240058308A1 (en) * | 2021-01-12 | 2024-02-22 | The Regents Of The University Of Michigan | Treatment and prevention of dry macular degeneration |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4454151A (en) * | 1982-03-22 | 1984-06-12 | Syntex (U.S.A.) Inc. | Use of pyrrolo pyrroles in treatment of ophthalmic diseases |
| US4515722A (en) * | 1982-03-30 | 1985-05-07 | Merck & Co., Inc. | Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents |
| US4474806A (en) * | 1982-05-10 | 1984-10-02 | Merck & Co., Inc. | Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents |
| US4952396A (en) * | 1986-11-19 | 1990-08-28 | Linus Pauling Institute Of Science & Medicine | Method of using phytic acid for inhibiting tumor growth |
| US4847082A (en) * | 1987-01-21 | 1989-07-11 | Robert Sabin | Method of treatment of Alzheimer's disease using phytic acid |
| US4758430A (en) * | 1987-01-21 | 1988-07-19 | Robert Sabin | Method of treatment of Alzheimer's disease using phytic acid |
| SE8904355D0 (sv) * | 1989-12-21 | 1989-12-21 | Perstorp Ab | Medicament |
| US5217959A (en) * | 1990-09-06 | 1993-06-08 | Robert Sabin | Method of treating multiple sclerosis with phytic acid |
| US5112814A (en) * | 1990-10-24 | 1992-05-12 | Robert Sabin | Method of treatment of Parkinson's disease using phytic acid |
| KR0185215B1 (ko) * | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| SE9102068L (sv) * | 1991-07-03 | 1993-01-04 | Perstorp Ab | Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav |
| SE469260B (sv) * | 1992-02-25 | 1993-06-14 | Perstorp Ab | En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat |
| NZ314111A (en) * | 1992-10-05 | 1997-08-22 | Virginia Tech Intell Prop | Preparation of d-chiro-inositol by reducing d-chiro-3-inosose |
| US5643562A (en) * | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
| US5972328A (en) * | 1993-03-29 | 1999-10-26 | Queen's University At Kingston | Method for treating amyloidosis |
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| DK0619369T3 (da) * | 1993-04-05 | 2003-10-06 | Aveve Nv | Phytathydrolyse og enzymsammensætning til hydrolyse af phytat |
| ES2130440T3 (es) * | 1993-08-11 | 1999-07-01 | Hokko Chem Ind Co | Proceso para producir d-(quiro)-inositol. |
| SE502574C2 (sv) * | 1994-01-25 | 1995-11-13 | Perstorp Ab | En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat |
| US5858326A (en) * | 1995-06-06 | 1999-01-12 | Neurochem, Inc. | Methods of increasing amyloid deposition |
| US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| US6232486B1 (en) * | 1996-06-11 | 2001-05-15 | Nutrimed Biotech | Molecular probes and modulators for PI-PLC and PI 3-kinase |
| US5880099A (en) * | 1996-09-20 | 1999-03-09 | The Regents Of The University Of California | Inositol polyphosphates and methods of using same |
| US5977078A (en) * | 1996-09-20 | 1999-11-02 | The Regents Of The Univesity Of California | Inositol polyphosphate derivatives and methods of using same |
| US5998485A (en) * | 1997-06-16 | 1999-12-07 | Cedars-Sinai Medical Center | Method for modulating immune response with inositol |
| US6153603A (en) * | 1997-06-27 | 2000-11-28 | Perstorp Ab | Method of treating angiogenesis in tumor tissue |
| US6310073B1 (en) * | 1998-07-28 | 2001-10-30 | Queen's University At Kingston | Methods and compositions to treat glycosaminoglycan-associated molecular interactions |
| US6818430B1 (en) * | 1999-06-07 | 2004-11-16 | Hokko Chemical Industry Co., Ltd. | Process for producing L-epi-2-inosose and novel process for producing epi-inositol |
| US6329256B1 (en) * | 1999-09-24 | 2001-12-11 | Advanced Micro Devices, Inc. | Self-aligned damascene gate formation with low gate resistance |
| NZ518685A (en) * | 1999-10-18 | 2004-04-30 | Muscletech Res And Dev Inc | Whey protein derivatives as food supplements that increase nitric oxide production in the body to enhance muscle size and strength |
| US7728043B2 (en) * | 1999-10-22 | 2010-06-01 | Kim Darrick S H L | Methods for treatment of beta-amyloid protein-induced ocular disease |
| US6887898B1 (en) * | 1999-10-22 | 2005-05-03 | Darrick S. H. L. Kim | Pharmaceutical compositions useful in prevention and treatment of beta-Amyloid protein-induced disease |
| US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| DE10031955A1 (de) * | 2000-06-30 | 2002-01-17 | Deutsches Krebsforsch | Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel |
| CA2437561A1 (en) * | 2001-02-06 | 2002-08-15 | Qlt Inc. | Use of additional photodynamic therapy in the treatment of choroidal neovasculature |
| AU2002236988A1 (en) * | 2001-02-06 | 2002-08-19 | Novartis Ag | Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration |
| US20030181531A1 (en) * | 2003-02-11 | 2003-09-25 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| WO2003007944A1 (en) * | 2001-07-20 | 2003-01-30 | Qlt, Inc. | Treatment of macular edema with photodynamic therapy |
| US20040058313A1 (en) * | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| ATE458042T1 (de) * | 2003-10-14 | 2010-03-15 | Hokko Chem Ind Co | Verfahren zur herstellung von scyllo-inositol |
| EP1841460A2 (en) * | 2004-06-18 | 2007-10-10 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| EP2186518A1 (en) * | 2004-11-17 | 2010-05-19 | McLaurin, Joanne | Composition and methods for treatment of disorders of protein aggregation |
| EP2656839A1 (en) * | 2007-04-12 | 2013-10-30 | Waratah Pharmaceuticals, Inc. | Use of Cyclohexanehexol Derivatives in the Treatment of Ocular Diseases |
-
2009
- 2009-10-09 JP JP2011530339A patent/JP2012505162A/ja active Pending
- 2009-10-09 CA CA2740124A patent/CA2740124A1/en not_active Abandoned
- 2009-10-09 WO PCT/CA2009/001448 patent/WO2010040232A1/en not_active Ceased
- 2009-10-09 AU AU2009301603A patent/AU2009301603A1/en not_active Abandoned
- 2009-10-09 EP EP09818730A patent/EP2349233A4/en not_active Withdrawn
- 2009-10-09 US US12/576,957 patent/US20100093648A1/en not_active Abandoned
-
2011
- 2011-04-08 ZA ZA2011/02640A patent/ZA201102640B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012505162A5 (cg-RX-API-DMAC7.html) | ||
| AU2023251388B2 (en) | Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells | |
| Nicoló et al. | Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy | |
| Ray et al. | Treatment of Coats’ disease with intravitreal bevacizumab | |
| CA3045733A1 (en) | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases | |
| JP2018529693A5 (cg-RX-API-DMAC7.html) | ||
| US11865123B2 (en) | Methods of inhibiting pathological angiogenesis | |
| JP2015509500A5 (cg-RX-API-DMAC7.html) | ||
| JP7730816B2 (ja) | 過剰血管新生に関連する眼疾患を治療する化合物 | |
| Keorochana et al. | Efficacy and safety of an extemporaneous preparation of 2% ganciclovir eye drops in CMV anterior uveitis | |
| CN105050600A (zh) | 眼底疾病治疗剂 | |
| Entezari et al. | Changes in retinal nerve fiber layer thickness after two intravitreal bevacizumab injections for wet type age-related macular degeneration | |
| WO2013184650A3 (en) | Treatment of ocular inflammatory diseases using laquinimod | |
| TN2016000259A1 (en) | Salbutamol (albuterol) eye protective medicament. | |
| Wood et al. | Rare corneal complication following selective laser trabeculoplasty | |
| Galloway et al. | The Ageing Eye | |
| Esquenazi | Cystoid macular edema in a pseudophakic patient after switching from latanoprost to BAK-free travoprost | |
| Kim et al. | Clinical Efficacy of Topical Diquafosol Tetrasodium after Laser Epithelial Keratomileusis. | |
| Kirtani et al. | Advanced Glaucoma in Angle Closure in a One-Eyed Patient: Can Surgery Be the Last Savior for the Vision? | |
| Lamas et al. | Coats Disease in Young Patient with Congenital Cataracts History | |
| HK40071471A (en) | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion | |
| Francis et al. | Eye and Orbit | |
| Wen-Ying et al. | Effect of absorbable lacrimal plug on function of tear film after femto-laser in situ keratomileusis | |
| O’Brien | Optimizing refractive outcomes in the presence of ocular allergy-toward a comprehensive approach to ocular surface health | |
| Lafaut et al. | LATE RADIATION RETINOPATHY IN A PATIENT TREATED FOR RETINOBLASTOMA |